This phase 1, multicenter, open-label study is designed to find the RP2D of volasertib, a
PLK1 inhibitor, and belinostat, an HDAC inhibitor, when given in combination to patients with
relapsed or refractory B-cell or T-cell lymphoma. A standard 3+3 dose-escalation design will
be employed with study enrollment beginning at dose level 1.